-- Positive trends continue as more patients receive treatment with WU-CART-007 in this study exploring the drug’s potential in improving standard of care ---- WU-CART-007 continues to demonstrate favorable tolerability…
Read More-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in Hard-to-Treat T-ALL/LBL Patients ---- Results from…
Read More— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML — — Wugen Earns FDA Orphan Drug Designation for WU-NK-101 for…
Read More-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- -- WU-CART-007 demonstrated preliminary evidence of anti-leukemic activity; achieved 57%…
Read More-- First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with R/R T-ALL/LBL -- -- Additional clinical data showcase the…
Read More-- Veteran biopharmaceutical executive Mark Alles brings more than three decades of global hematology and oncology experience, and significant corporate governance expertise -- ST. LOUIS, MO and SAN DIEGO, CA,…
Read More-- Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) -- -WU-NK-101 demonstrated PD-L1 and MHC-I checkpoint upregulation in solid tumor models- --…
Read More-- Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance -- ST. LOUIS, MO and SAN DIEGO, CA, March 29, 2023…
Read More-- Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer -- ST. LOUIS, MO and SAN DIEGO, CA, March 21, 2023 –Wugen, Inc., a clinical-stage biotechnology company developing a…
Read More-- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- --WU-NK-101 exhibited robust trafficking, intra-tumor infiltration, and persistence in xenograft tumor models which were further enhanced…
Read MoreCopyright © 2025 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design
